Sugi Predict

Sugi Predict / Targets / CHUK

CHUK

Inhibitor of nuclear factor kappa-B kinase subunit alpha · O15111 · CHUK on Sugi Atlas →

65,814 patent compounds predicted against CHUK, 44,743 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Bms-345541 Bms-345541 (SCHEMBL118886) 1.00 16/20
SCHEMBL94358 SCHEMBL94358 0.56 14/20
SCHEMBL246359 SCHEMBL246359 0.51 10/20
Norharmane Norharmane (SCHEMBL25834) 1.00 7/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL70622) 0.53 7/20
SCHEMBL100470 SCHEMBL100470 0.48 7/20
SCHEMBL101575 SCHEMBL101575 0.46 6/20
SCHEMBL245342 SCHEMBL245342 0.61 4/20
SCHEMBL245343 SCHEMBL245343 0.61 4/20
SCHEMBL187501 SCHEMBL187501 0.51 4/20
SCHEMBL122073 SCHEMBL122073 0.49 4/20
SCHEMBL239630 SCHEMBL239630 0.47 4/20
SCHEMBL175564 SCHEMBL175564 0.36 4/20
SCHEMBL103099 SCHEMBL103099 0.69 3/20
SCHEMBL154683 SCHEMBL154683 0.61 3/20
SCHEMBL164881 SCHEMBL164881 0.58 3/20
SCHEMBL99011 SCHEMBL99011 0.54 3/20
SCHEMBL99690 SCHEMBL99690 0.52 3/20
SCHEMBL99190 SCHEMBL99190 0.51 3/20
SCHEMBL100434 SCHEMBL100434 0.45 3/20

Clinical trials — most relevant to CHUK by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease PHASE4COMPLETED
Enhancing Effect on Tumour Apoptosis With the Use of Pentoxifylline in Patients With Hodgkin Lymphoma PHASE4UNKNOWN
Dexmedetomidine to Prevent Hepatic Ischemia-reperfusion Injury-induced Glycocalyx Degradation and Early Allograft Dysfunction in Liver Transplantation PHASE4ACTIVE_NOT_RECRUITING
GLP-1 Receptor Agonists in Non-diabetic Patients With Psoriatic Arthritis PHASE4NOT_YET_RECRUITING
Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk PHASE2/PHASE3COMPLETED
The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room PHASE2/PHASE3COMPLETED
Erythropoietin (EPO) and Ischemia-reperfusion After Kidney Transplantation PHASE2/PHASE3COMPLETED
Effect of Silymarin in Metastatic Colorectal Cancer Patients PHASE3UNKNOWN
Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi. PHASE3COMPLETED
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma PHASE2COMPLETED
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients PHASE1/PHASE2COMPLETED
Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients PHASE1/PHASE2COMPLETED
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors PHASE2COMPLETED
Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia PHASE2COMPLETED
Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC PHASE2COMPLETED
Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients PHASE2COMPLETED
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer PHASE1COMPLETED
Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma PHASE1COMPLETED
Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma PHASE1COMPLETED
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma PHASE1COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers PHASE1COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Novel Biomarkers in Inflammatory Bowel Disease nanCOMPLETED
IKBKB Gene Polymorphism (Single Nucleotide Polymorphism) (SNP) in Psoriatic and Psoriatic Arthritis Patients nanCOMPLETED
Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA. nanRECRUITING
The Beneficial Effects of Pomegranate on Hearing of Patients Without Hemodialysis nanCOMPLETED
Card14gene (rs34367357 ) Polymorphism in Egyptian Psoriatic and Psoriatic Arthritis Patient nanRECRUITING
Immune Interactions in Severe Asthma nanCOMPLETED
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia nanUNKNOWN
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients. nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CHUK binder may also engage these)

ProteinNameSimilarity
Q95KV1 — 1.000 Q95KV1 →
Q6GM53 — 1.000 Q6GM53 →
Q60680 — 1.000 Q60680 →
Q28DZ1 — 1.000 Q28DZ1 →
Q5ZJB4 — 1.000 Q5ZJB4 →
Q95KV0 — 1.000 Q95KV0 →
IKBKB Inhibitor of nuclear factor kappa-B kinase subunit beta 1.000 landscape →
Q4G3H4 — 1.000 Q4G3H4 →
Q9VEZ5 — 0.998 Q9VEZ5 →
Q9QY78 — 0.997 Q9QY78 →
O88351 — 0.997 O88351 →
Q6XUX1 — 0.996 Q6XUX1 →
Q8BX57 — 0.995 Q8BX57 →
Q4VSN4 — 0.995 Q4VSN4 →
Q94C95 — 0.995 Q94C95 →
Q9Z2R9 — 0.995 Q9Z2R9 →
Q4R8E0 — 0.994 Q4R8E0 →
KDM5D Lysine-specific demethylase 5D 0.993 landscape →
Q9LX30 — 0.993 Q9LX30 →
O97143 — 0.993 O97143 →
Q9D3R6 — 0.993 Q9D3R6 →
Q6XUX0 — 0.993 Q6XUX0 →
O12990 — 0.993 O12990 →
KDM5B Lysine-specific demethylase 5B 0.993 landscape →
DHX29 ATP-dependent RNA helicase DHX29 0.993 landscape →
Q811U4 — 0.993 Q811U4 →
Q8R4Z9 — 0.993 Q8R4Z9 →
G5EFD2 — 0.993 G5EFD2 →
Q4V9P9 — 0.993 Q4V9P9 →
P10911 — 0.993 P10911 →